Insilico Medicine (03696.HK) announced on September 21 midday a partnership with a frontier foundation model laboratory, with a contract value of up to tens of millions of dollars, to jointly develop, validate, and commercialize frontier foundation models purpose-built for biology research using Insilico's proprietary MMAI Gym training framework. Insilico will provide proprietary datasets covering multiple specialized life science tasks and conduct closed-loop wet-lab validation, with a revenue-sharing model established between the parties. Following the announcement, shares surged nearly 6% in afternoon trading, reaching an intraday high of HK$64.35, with gains briefly expanding to approximately 5.84%; as of press time, the stock was up 4.52% at HK$63.5, with turnover reaching HK$1.181 billion. In the first half of 2026, the company reported total revenue of approximately $106 million, up 287.2% year-over-year, net profit of $35.54 million and adjusted net profit of $51.23 million, achieving a turnaround to profitability with positive operating cash flow. Revenue growth was primarily driven by out-licensing deals, with the potential total value of new transactions signed during the year reaching approximately $7.3 billion, bringing the cumulative total to $11 billion.